T1	intervention 96 106	filgrastim
T2	condition 134 153	febrile neutropenia
T3	eligibility 578 629	Early breast cancer patients receiving chemotherapy
T4	outcome-Measure 972 1004	patient and physician engagement
T5	outcome-Measure 1168 1196	first occurrence rates of FN
T6	outcome-Measure 1198 1234	treatment-related hospital admission
T7	outcome-Measure 1239 1290	chemotherapy dose reductions/delays/discontinuation
T8	duration 1292 1320	From May 2015 to August 2016
T9	No-of-participants 1322 1325	142
T10	No-of-participants 1401 1410	Seventeen
T11	No-of-participants 1485 1488	142
T12	outcome 1546 1594	Aggregate incidences of a first event by patient
T13	outcome 1600 1602	FN
T14	outcome 1618 1651	treatment-related hospitalization
T15	outcome 1667 1695	chemotherapy discontinuation
T16	outcome 1711 1730	chemotherapy delays
T17	outcome 1750 1777	chemotherapy dose reduction
T18	intervention-value 1604 1605	8
T19	No-of-participants 1606 1609	142
T20	intervention-value 1611 1615	5.6%
T21	intervention-value 1653 1654	6
T22	No-of-participants 1655 1658	142
T23	intervention-value 1660 1664	4.2%
T24	intervention-value 1697 1698	7
T25	No-of-participants 1699 1702	142
T26	intervention-value 1704 1708	4.9%
T27	intervention-value 1732 1733	5
T28	No-of-participants 1734 1737	142
T29	intervention-value 1739 1743	3.5%
T30	intervention-value 1779 1781	18
T31	No-of-participants 1782 1785	142
T32	intervention-value 1787 1792	12.7%
